Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease

Christina M. Barriteau, Sherif M. Badawy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Sickle cell disease (SCD) is one of the most common inherited blood disorders. Deoxygenated hemoglobin S (HbS) polymerizes and causes anemia and various end organ effects. Voxelotor acts by increasing HbS oxygen affinity, decreasing anemia and hemolysis. Voxelotor is approved for use in individuals with SCD age 4 years and older. Phase 3 trials demonstrated an increase in hemoglobin levels and a decrease in markers of hemolysis; however, data or benefits related to clinical and quality of life outcomes are relatively limited and varied across different studies. This review summarizes the published clinical trials and research studies focused on the use of voxelotor in SCD to provide an evidence-based practical guide for hematology providers on its utilization in clinical settings, including physicians and independent licensed practitioners.

Original languageEnglish (US)
Pages (from-to)739-745
Number of pages7
JournalJournal of Blood Medicine
StatePublished - 2022


  • adolescents
  • adult
  • children
  • disease-modifying therapy
  • hemoglobinopathy
  • oxbryta
  • pediatric
  • sickle cell
  • sickle cell anemia
  • sickle cell disease
  • voxelotor
  • young adults

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Practical Guidance for the Use of Voxelotor in the Management of Sickle Cell Disease'. Together they form a unique fingerprint.

Cite this